Ravulizumab in neuromyelitis optica spectrum disorder: first clinical experience in Chile
BackgroundNeuromyelitis optica spectrum disorder (NMOSD) is a neuroimmunological astrocytopathy mediated by anti-aquaporin-4 (AQP4-IgG) antibodies that trigger complement-dependent cytotoxicity and activation of the terminal complement cascade in the c…